Humana Raises 2026 Profit Outlook To At Least $9.50 A Share After Smaller Third-Quarter Loss

The insurer still expects full-year adjusted earnings to fall from $17.14 a share in 2025 as weaker Star Ratings cut quality bonuses.

Share
Humana Raises 2026 Profit Outlook To At Least $9.50 A Share After Smaller Third-Quarter Loss

Humana, the health insurer, lifted its 2026 adjusted earnings outlook to at least $9.50 a share from at least $9.00 on Friday, after an adjusted third-quarter loss of $0.70 a share.

A loss, but a better medical-cost ratio

Humana, which sells Medicare and other government-program health plans and runs CenterWell pharmacies, primary care clinics and home health services, posted a GAAP profit of $1.33 a share for the quarter. On the adjusted measure it lost $0.70, against earnings of $3.24 a year earlier.

The Insurance segment's benefit ratio, the share of premiums paid out in medical and drug costs, was 93.7%, better than management's guidance of "slightly above 94 percent." A year earlier it was 91.1%.

Revenue rose to $41,155 million from $32,649 million, but the Insurance segment lost $303 million from operations on a GAAP basis, against a $251 million profit a year earlier. CenterWell earned $243 million, down from $305 million.

Why GAAP and adjusted guidance diverge

Humana now guides to GAAP earnings of at least $15.09 a share, up from at least $6.52. The gap to the adjusted figure comes largely from non-cash items: put/call valuation adjustments on minority investments, which lowered third-quarter pretax results by $358 million in the reconciliation to adjusted results.

The full-year GAAP guidance includes the noncash reversal of a net put liability of about $1.2 billion tied to CenterWell Senior Primary Care's earlier joint ventures with Welsh, Carson, Anderson & Stowe. A new joint venture with HPS Investment Partners, a BlackRock subsidiary, replaced them. The company said it improves balance sheet efficiency and lowers the cost of capital.

Star Ratings still weigh on the year

Humana said the adjusted guidance still implies a decline from $17.14 a share in 2025, because of the Star Ratings headwind for bonus year 2026. The company appealed a court decision rejecting its challenge to its 2025 Star Ratings, and warned that a loss would hurt 2026 quality bonus payments from CMS.

CEO Jim Rechtin said Humana is "increasingly driving financial and operating performance toward being "ahead" of our plan." CenterWell Senior Primary Care added 146,800 patients, or 30%, year to date, and Medicaid membership grew by 103,600, or 7%.

Humana will hold a virtual investor update on December 10, 2026, to measure progress against its Investor Day framework.

Sources

More on Humana

All Humana (HUM) coverage →